Note

. Net

(

Loss

)

Income

Per Share

Our basic net

(loss) income per share attributable to Progenics amounts have been computed by dividing net (loss) income attributable to Progenics by the weighted-average number of common shares outstanding during the period. For the

three

and

nine

months ended

September 30, 2017,

we reported net losses and, accordingly, potential common shares were

not

included since such inclusion would have been anti-dilutive. For the

three

and

nine

months ended

September 30, 2016,

we reported net income, and the computation of diluted earnings per share is based upon the weighted-average number of our common shares and dilutive effect of stock options (determined using the treasury stock method).

The calculations of net

(loss) income per share, basic and diluted, are as follows (amounts in thousands, except per share data):

	Net (Loss)
	Income		Weighted-Average
	Attributable		Shares
	to Progenics		Outstanding		Per Share
	(Numerator)		(Denominator)		Amount
Three months ended September 30, 2017
Basic and diluted	$	(15,352)		70,270	$	(0.22)
Nine months ended September 30, 2017
Basic and diluted	$	(48,348)		70,233	$	(0.69)
Three months ended September 30, 2016
Basic	$	36,303		70,013	$	0.52
Dilutive effect of stock options		-		284
Diluted	$	36,303		70,297	$	0.52
Nine months ended September 30, 2016
Basic	$	18,010		69,970	$	0.26
Dilutive effect of stock options		-		36
Diluted	$	18,010		70,006	$	0.26

The following table summarizes anti-dilutive common shares

or common shares where performance conditions have

not

been met, that were excluded from the calculation of diluted net (loss) income per share (in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,
	2017		2016		2017		2016
Stock options		3,061		3,332		1,989		5,127
Contingent consideration liability		2,378		3,342		2,378		3,946
Total securities excluded		5,439		6,674		4,367		9,073